Effect of long-term administration of a prolonged release formulation of bovine somatotropin (sometribove) on clinical lameness in dairy cows

S. J. Wells From the Department of Clinical and Population Sciences, College of Veterinary Medicine, University of Minnesota, St Paul, MN 55108 (Wells, Trent), and Monsanto Company, Animal Sciences Division, Chesterfield, MO 63198 (Collier, Cole).

Search for other papers by S. J. Wells in
Current site
Google Scholar
PubMed
Close
 DVM, PhD
,
A. M. Trent From the Department of Clinical and Population Sciences, College of Veterinary Medicine, University of Minnesota, St Paul, MN 55108 (Wells, Trent), and Monsanto Company, Animal Sciences Division, Chesterfield, MO 63198 (Collier, Cole).

Search for other papers by A. M. Trent in
Current site
Google Scholar
PubMed
Close
 DVM, MVSc
,
R. J. Collier From the Department of Clinical and Population Sciences, College of Veterinary Medicine, University of Minnesota, St Paul, MN 55108 (Wells, Trent), and Monsanto Company, Animal Sciences Division, Chesterfield, MO 63198 (Collier, Cole).

Search for other papers by R. J. Collier in
Current site
Google Scholar
PubMed
Close
 PhD
, and
W. J. Cole From the Department of Clinical and Population Sciences, College of Veterinary Medicine, University of Minnesota, St Paul, MN 55108 (Wells, Trent), and Monsanto Company, Animal Sciences Division, Chesterfield, MO 63198 (Collier, Cole).

Search for other papers by W. J. Cole in
Current site
Google Scholar
PubMed
Close
 DVM

SUMMARY

A matched case-control study design was used to assess the effects of long-term administration of a prolonged release formulation of bovine somatotropin (sometribove) on clinical lameness and limb lesions in dairy cows. Cows treated with sometribove for at least 2 lactations (cases) and nontreated dairy cows matched by herd, parity, age, and stage of lactation (controls) in 8 herds were evaluated for clinical lameness (as assessed by gait abnormality) and limb lesions by 2 observers, using a standardized scoring procedure at a single herd visit. Although a high proportion of the study cows were clinically lame (43%), an association was not detected between chronic administration of sometribove and prevalent lameness. Of 21 types of limb lesions identified, 2 were positively associated and 2 were negatively associated with long-term sometribove use. Superficial laceration of the tarsus (odds ratio [or] = 2.1) and superficial swelling of the metatarsophalangeal joint (or = 4.5) were positively associated with sometribove treatment, whereas femoral lesions (or = 0.2) and superficial lacerations of the femur (or = 0.14) were negatively associated with sometribove treatment.

SUMMARY

A matched case-control study design was used to assess the effects of long-term administration of a prolonged release formulation of bovine somatotropin (sometribove) on clinical lameness and limb lesions in dairy cows. Cows treated with sometribove for at least 2 lactations (cases) and nontreated dairy cows matched by herd, parity, age, and stage of lactation (controls) in 8 herds were evaluated for clinical lameness (as assessed by gait abnormality) and limb lesions by 2 observers, using a standardized scoring procedure at a single herd visit. Although a high proportion of the study cows were clinically lame (43%), an association was not detected between chronic administration of sometribove and prevalent lameness. Of 21 types of limb lesions identified, 2 were positively associated and 2 were negatively associated with long-term sometribove use. Superficial laceration of the tarsus (odds ratio [or] = 2.1) and superficial swelling of the metatarsophalangeal joint (or = 4.5) were positively associated with sometribove treatment, whereas femoral lesions (or = 0.2) and superficial lacerations of the femur (or = 0.14) were negatively associated with sometribove treatment.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 1667 1643 245
PDF Downloads 51 43 0
Advertisement